Sumatriptan

A phase 3 study examined a low-dose subcutaneous autoinjection of sumatriptan in the acute treatment of migraines with or without aura in adults.

DFN-02 nasal spray may be effective, well tolerated, and safe for the acute treatment of episodic migraine.

DFN-02 was evaluated in a multicenter, double-blind, randomized, placebo-controlled study (N=107) which showed it was effective in treating pain and associated symptoms during a migraine attack and in reducing attack-related functional disability.

Sumavel DosePro was approved in 2009 for the acute treatment of migraine or cluster headaches as a needle-free delivery system supplied in prefilled pens, and is being discontinued.

The use of intranasal sumatriptan is an effective treatment for patients with acute migraine attacks; however, future investigations are needed to better understand differences in routes of administration and other therapies for migraine.

Nasal administration of sumatriptan powder in patients with migraine results in quicker reductions in pain intensity and migraine-related disability compared with oral sumatriptan.